Program
Insulin Glargine
Also written as “insulin glargine”, “Insulin glargine” and “INSULIN GLARGINE”.
Its studies are mostly in Diabetes Mellitus, Type 2 · Diabetes Mellitus, Type 1 · Diabetes Mellitus · Hyperglycemia · Glucose Intolerance, led by 9 companies.
Drug pageInsulin Glargine: every studyMany companies study it; this page follows only the 184 they lead. All 294 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Sanofiits history only | 1241 open or running | phase 4since Sep 9, 2005 | Sep 30, 2002 | none ahead |
| Novo Nordisk | 280 open or running | phase 4since Sep 12, 2005 | Oct 29, 2004 | none ahead |
| Eli Lillyits history only | 250 open or running | phase 4since Sep 12, 2005 | Sep 12, 2005 | none ahead |
| Diabetes Care Centerits history only | 20 open or running | no phasesince Apr 3, 2007 | Apr 3, 2007 | none ahead |
| Biodelits history only | 10 open or running | phase 2since Oct 21, 2009 | Oct 21, 2009 | none ahead |
| Geropharmits history only | 10 open or running | no phasesince Sep 23, 2019 | Sep 23, 2019 | none ahead |
| ikfe-CROits history only | 10 open or running | phase 4since Dec 5, 2011 | Dec 5, 2011 | none ahead |
| Profil Institut für Stoffwechselforschungits history only | 10 open or running | phase 1since Sep 3, 2009 | Sep 3, 2009 | none ahead |
| Wockhardtits history only | 10 open or running | phase 1since May 12, 2011 | May 12, 2011 | none ahead |
Also a collaborator on its studies: PPD DEVELOPMENT, LP, Alkermes and Boehringer Ingelheim.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Novo Nordisk only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 13 studies since Oct 29, 2004.
- Jan 14, 2009Phase 1 study in Diabetes MellitusNCT00824668 · 24 enrolled · Germany
- Aug 17, 2009Phase 1 study in Diabetes MellitusNCT00961324 · 54 enrolled · Germany
- Oct 26, 2009Phase 1 study in Diabetes MellitusNCT01002768 · 28 enrolled · Austria
- Oct 30, 2009Phase 3 study in Diabetes MellitusNCT01006291 · 687 enrolled · Argentina, Finland, Hungary and more
- Jan 8, 2010Phase 3 study in Diabetes MellitusNCT01045707 · 530 enrolled · United States, Austria, India and more
- May 31, 2010Phase 3 study in Diabetes MellitusNCT01135992 · 143 enrolled · United States
- Dec 20, 2011Phase 1 study in Diabetes MellitusNCT01497574 · 32 enrolled · Germany
- Apr 2, 2012Phase 3 study in Diabetes MellitusNCT01570751 · 145 enrolled · United States, Puerto Rico
- Oct 8, 2012Phase 1 study in Diabetes MellitusNCT01704417 · 40 enrolled · Germany
- Nov 6, 2012Phase 1 study in Diabetes MellitusNCT01730014 · 70 enrolled · Germany
- May 6, 2013Phase 3 study in Diabetes MellitusNCT01849289 · 833 enrolled · United States, Brazil, Canada and more
- May 30, 2013Phase 1 study in Diabetes MellitusNCT01868529 · 63 enrolled · Germany
- Jan 7, 20142 phase 3 studies in Diabetes MellitusNCT02034513, NCT02030600
- Mar 26, 2024Phase 3 study in Diabetes Mellitus, Type 2NCT06340854 · 412 enrolled · United States, Bulgaria, Germany and more
TargetBeta
“Insulin receptor agonist”ChEMBL 37, by rule
Other programs on INSR
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Insulin Aspartrule | Novo Nordisk | phase 4 | 146 |
| insulin degludecrule | Novo Nordisk | phase 4 | 108 |
| Insulinrule | Pfizer | phase 4 | 50 |
| insulin glulisinerule | Sanofi | phase 4 | 43 |
| insulin icodecrule | Novo Nordisk | phase 4 | 30 |
| linsitinibrule | Astellas Pharma | phase 3 | 13 |
| LY3938577 | Eli Lilly | phase 2 | 3 |
Studies
All 28 Novo Nordisk leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06340854Diabetes Mellitus, Type 2 · United States, Bulgaria, Germany and more | 3 | Completed | May 8, 2025 | 412 |
| NCT02034513Diabetes Mellitus · United States, Poland, Puerto Rico | 3 | Completed | Jan 11, 2016 | 501 |
| NCT02030600Diabetes Mellitus · United States, Puerto Rico | 3 | Completed | Dec 4, 2015 | 721 |
| NCT01868529Diabetes Mellitus · Germany | 1 | Completed | Jun 2008 | 63 |
| NCT01849289Diabetes Mellitus · United States, Brazil, Canada and more | 3 | Completed | May 15, 2014 | 833 |
| NCT01730014Diabetes Mellitus · Germany | 1 | Completed | Jul 2013 | 70 |
| NCT01704417Diabetes Mellitus · Germany | 1 | Completed | Mar 2013 | 40 |
| NCT01570751Diabetes Mellitus · United States, Puerto Rico | 3 | Completed | Jan 2014 | 145 |
| NCT01497574Diabetes Mellitus · Germany | 1 | Completed | Oct 2005 | 32 |
| NCT01135992Diabetes Mellitus · United States | 3 | Completed | Nov 2010 | 143 |
| NCT01045707Diabetes Mellitus · United States, Austria, India and more | 3 | Completed | Oct 2010 | 530 |
| NCT01006291Diabetes Mellitus · Argentina, Finland, Hungary and more | 3 | Completed | Sep 2010 | 687 |
| NCT01002768Diabetes Mellitus · Austria | 1 | Completed | Mar 2010 | 28 |
| NCT00961324Diabetes Mellitus · Germany | 1 | Completed | Oct 26, 2009 | 54 |
| NCT00824668Diabetes Mellitus · Germany | 1 | Completed | Oct 2007 | 24 |
| NCT00619697Diabetes Mellitus · Austria, Czech Republic, Germany and more | 4 | Completed | Mar 2005 | 260 |
| NCT00612040Diabetes Mellitus · United States, Australia, Germany and more | 2 | Completed | Jun 2008 | 178 |
| NCT00598793Diabetes Mellitus · United States | 3 | Completed | Mar 2004 | 242 |
| NCT00331851Diabetes Mellitus · Argentina, Austria, Brazil and more | 3 | Completed | Apr 2007 | 584 |
| NCT00313742Diabetes Mellitus · Germany, United Kingdom | 4 | Completed | Nov 2006 | 51 |
| NCT00312104Diabetes Mellitus · Austria, Germany, South Africa | 3 | Completed | Mar 2003 | 325 |
| NCT00283751Diabetes Mellitus · United States, Austria, Belgium and more | 3 | Completed | Nov 2004 | 583 |
| NCT00184626Diabetes Mellitus · Turkey | 4 | Completed | Oct 24, 2005 | 97 |
| NCT00184613Diabetes Mellitus · Denmark | 1 | Completed | Jan 2006 | 22 |
| NCT00106366Diabetes Mellitus · United States, Canada, Puerto Rico | 3 | Completed | Dec 2005 | 389 |
| NCT00097877Diabetes Mellitus · United States, Puerto Rico | 3 | Completed | Nov 2006 | 293 |
| NCT00097084Diabetes Mellitus · United States, Finland, France and more | 3 | Completed | Dec 2005 | 324 |
| NCT00095082Diabetes Mellitus · United States, Finland, France and more | 3 | Completed | Dec 2005 | 447 |
How it is read
Names in the registry
- “insulin glargine”, 38 entries
- “Insulin Glargine”, 27 entries
- “Insulin glargine”, 20 entries
- “INSULIN GLARGINE”, 15 entries
- “LY2963016”, 11 entries
Codes read as this program: HOE901.
Conditions, from the studies’ own filings
- Diabetes Mellitus, Type 2, 124 studies
- Diabetes Mellitus, Type 1, 44 studies
- Diabetes Mellitus, 14 studies
- Hyperglycemia, 1 study
- Glucose Intolerance, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.